Loading organizations...
§ Private Profile · Pingdingshan, Henan, China
Biotech company developing, manufacturing, commercializing novel drugs for viral, oncology, and cardio-cerebrovascular diseases.
Genuine Biotech is a Pingdingshan, China-based biotechnology company that develops, manufactures, and commercializes novel therapeutics for viral infections, oncology, and cardio-cerebrovascular diseases. The organization focuses on addressing drug resistance and unmet medical needs through its proprietary clinical pipeline, highlighted by azvudine, a Class 1.1 innovative drug that received conditional approval for the treatment of HIV and COVID-19. Alongside its antiviral portfolio, the firm advances oncology treatments like dosimertinib for lung cancer while operating a GMP-compliant manufacturing facility. To support its research and development operations across centers in Shenzhen and Shanghai, the enterprise completed a $100 million Series B financing round in August 2021. This capital raise was backed by a syndicate of institutional investors including Efung Capital, Yingke PE, Desano, ABC Capital, and Fortune Financial Capital. Genuine Biotech was founded in 2012 by Wang Zhaoyang.
Genuine Biotech has raised $100.0M across 1 funding round.
Genuine Biotech has raised $100.0M in total across 1 funding round.
Genuine Biotech has raised $100.0M in total across 1 funding round.
Genuine Biotech's investors include Efung Capital.
Genuine Biotech has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series B in August 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 28, 2021 | $100M Series B | Efung Capital | — | Announced |